Objective
Prostate cancer is the most commonly diagnosed cancer among men, with an anticipated 1.7M new cases and 499,000 deaths by 2030 worldwide. Although, most cancer therapies available focus on treatment of the primary tumor, the leading cause of cancer morbidity and mortality is metastasis. Today’s current treatments for metastatic prostate cancer focus on later stage of the cancer progression, when the signs of metastasis spread are already observed; and modestly prolong the patient’s survival and have serious side effects. Therefore, there is a high unmet need for new therapies, which can effectively address the problem as the first adjuvant treatment against early stage of metastasis in prostate cancer.
RhoVac is a biotechnology company dedicated to the research and development of immunotherapies for the treatment of early stage metastatic cancer. The RV001 (RhoVac’s first product) vaccine is the first therapeutic vaccine against metastatic cancer cells, specifically targeting the prevention of cancer relapses. The concept behind RV001 relies on the reprogramming of the patient own T cells to recognise and eliminate early stage metastatic cancer cells.
Together with an unprecedented therapeutic potential in multiple cancer types, RV001 holds important competitive advantages, such as safety, tolerability and cost-effectiveness. However, to secure swift development and successful commercialization, RhoVac needs partnerships and capital to achieve RV001 clinical validation. In this context, we believe SME instrument will be crucial to position RV001 within the metastatic cancer treatment and to confirm the high pharma-economic value of our disruptive technology. The accomplishment of SME Phase 1 and Phase 2 project objectives will maximize the clinical value of our vaccine within the selected market and a lead to a significant business opportunity for RhoVac – revenues are expected to be around €350M, within 5 years of market approval, only in prostate cancer segment.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine oncology prostate cancer
- social sciences sociology demography mortality
- social sciences economics and business business and management business models
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences basic medicine immunology immunotherapy
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
2970 Horsholm
Denmark
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.